Combined detection of serum DKK1 and P53 autoantibodies for the diagnostic value of esophageal squamous cell carcinoma

doi:10.3760/cma.j.issn.1673-422X.2015.06.004

Abstract

Abstract: Objective To evaluate the diagnostic value of the combination of serum DKK1(Dickkopf1) and P53 autoantibodies in patients with esophageal squamous cell carcinoma (ESCC). Methods Serum levels of DKK1 and P53 autoantibodies were measured by enzymelinked immunosorbent assay (ELISA) for the 126 patients with ESCC and 60 normal controls. Receiver operating characteristics (ROC) was used to calculate the diagnostic efficiency. Results The serum levels of DKK1 and P53 autoantibodies were significantly higher in ESCC than those in normal controls ［(673.09±343.82)pg/ml vs (362.05±148.07)pg/ml, Z=6.158, P＜0.000 1; (0.398±0.546) vs (0.069±0.050), Z=3.832, P＜0.000 1］. ROC curves showed the optimum diagnostic cutoff for serum DKK1 was 588.77 pg/ml, with an area under curve (AUC) of 0.780 (95%CI: 0.715～0.844, 61.9% sensitivity, 95.0% specificity). Measurement of P53 autoantibodies demonstrated an AUC of 0.674 (95%CI: 0.598～0.750, 45.3% sensitivity, 95.0% specificity). The combination of DKK1 and P53 autoantibodies yielded an AUC of 0.843 (95%CI: 0.788～0.897, 73.8% sensitivity, 95.0% specificity). In early stage ESCC, combined detection of DKK1 and P53 autoantibodies improved the diagnostic power, with an AUC of 0.903 (95%CI: 0.845～0.961, 81.0% sensitivity, 95.0% specificity). Conclusion Serum DKK1 and P53 autoantibodies can be used as potential diagnostic biomarkers for the ESCC. Combined detection of them might aid the early diagnosis of ESCC.

Key words: Esophageal neoplasms, Diagnosis, Dickkopf-1, P53 autoantibody

Peng Yuhui, Chen Jianliang, Weng Xuefen, Fang Yusen, Xu Yiwei. Combined detection of serum DKK1 and P53 autoantibodies for the diagnostic value of esophageal squamous cell carcinoma[J]. Journal of International Oncology, 2015, 42(6): 414-418.

References

［1］ Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008［J］. Int J Cancer, 2010, 127(12): 2893-2917. ［2］ Arnold M, Soerjomataram I, Ferlay J, et al. Global incidence of oesophageal cancer by histological subtype in 2012［J］. Gut, 2015, 64(3): 381-387. ［3］ Menezes ME, Devine DJ, Shevde LA, et al. Dickkopf1: a tumor suppressor or metastasis promoter?［J］. Int J Cancer, 2012, 130(7): 1477-1483. ［4］ Feldmann R, Schierl M, Fink AM, et al. Serum levels of glycoprotein Dickkopf1 in patients with cutaneous malignant melanoma: a prospective pilot study［J］. Dermatology, 2011, 222(2): 171-175. ［5］ Shen Q, Fan J, Yang XR, et al. Serum DKK1 as a protein biomarker for the diagnosis of hepatocellular carcinoma: a largescale, multicentre study［J］. Lancet Oncol, 2012, 13(8): 817-826. ［6］ Yamabuki T, Takano A, Hayama S, et al. Dikkopf1 as a novel serologic and prognostic biomarker for lung and esophageal carcinomas［J］. Cancer Res, 2007, 67(6): 2517-2525. ［7］李波波, 李道堂, 刘曙光, 等. 食管癌患者血清中DKK-1的表达［J］. 山东大学学报: 医学版, 2009, 7(6):58-61. ［8］ Xu YW, Peng YH, Chen B, et al. Autoantibodies as potential biomarkers for the early detection of esophageal squamous cell carcinoma［J］. Am J Gastroenterol, 2014, 109(1): 36-45. ［9］中国非手术治疗食管癌临床分期专家小组. 非手术治疗食管癌的临床分期标准(草案)［J］. 中华放射肿瘤学杂志, 2010, 19(3): 179-180. ［10］ Glinka A, Wu W, Delius H, et al. Dickkopf-1 is a member of a new family of secreted proteins and functions in head induction［J］. Nature, 1998, 391(6665): 357-362. ［11］ Peifer M, Polakis P. Wnt signaling in oncogenesis and embryogenesis—a look outside the nucleus［J］. Science, 2000, 287(5458): 1606-1609. ［12］ Yang Y. Wnts and wing: Wnt signaling in vertebrate limb development and musculoskeletal morphogenesis［J］. Birth Defects Res C Embryo Today, 2003, 69(4): 305-317. ［13］ Desmetz C, Mange A, Maudelonde T, et al. Autoantibody signatures: progress and perspectives for early cancer detection［J］. J Cell Mol Med, 2011, 15(10): 2013-2024. ［14］ Zheng X, Xing S, Liu XM, et al. Establishment of using serum YKL-40 and SCCA in combination for the diagnosis of patients with esophageal squamous cell carcinoma［J］. BMC Cancer, 2014, 14: 490.

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou. Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer [J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Yuan Jian, Huang Yanhua. Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer [J]. Journal of International Oncology, 2024, 51(6): 338-343.
[4]	Liu Jing, Liu Qin, Huang Mei. Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm [J]. Journal of International Oncology, 2024, 51(5): 267-273.
[5]	Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi. Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer [J]. Journal of International Oncology, 2024, 51(5): 286-291.
[6]	Chen Qi, Xu Chenyang, Wang Yin, Lei Dapeng. Current application status of hyperspectral imaging in the diagnosis and treatment of head and neck tumor [J]. Journal of International Oncology, 2024, 51(5): 298-302.
[7]	Wan Fang, Yang Gang, Li Rui, Wan Qijing. Expression levels and clinical significance of serum miR-497 and miR-383 in patients with esophageal cancer [J]. Journal of International Oncology, 2024, 51(4): 204-209.
[8]	Zhang Lili, Tan Ru, Fang Xueli, Yang Yu, Sang Zheng, Li Baosheng. Imaging diagnosis， pathological upgrade， and imaging technology progress of ductal carcinoma in situ of the breast [J]. Journal of International Oncology, 2024, 51(3): 166-169.
[9]	Peng Qin, Cai Yuting, Wang Wei. Advances on KPNA2 in liver cancer [J]. Journal of International Oncology, 2024, 51(3): 181-185.
[10]	Jin Xudong, Chen Zhongjian, Mao Weimin. Research progress on the role of MTAP in malignant mesothelioma [J]. Journal of International Oncology, 2024, 51(2): 99-104.
[11]	Gao Xinyu, Li Zhenjiang, Sun Hongfu, Han Dan, Zhao Qian, Liu Chengxin, Huang Wei. Clinical application of MR-guided radiotherapy based on MR-linac in esophageal cancer patients [J]. Journal of International Oncology, 2024, 51(1): 37-42.
[12]	Huang Zhen, Chen Yongshun. Research progress of circulating tumor DNA in the diagnosis and treatment of hepatocellular carcinoma [J]. Journal of International Oncology, 2024, 51(1): 59-64.
[13]	Wang Jing, Xu Wenting. Value of NLR， CEA combined with coagulation indicators in the differential diagnosis of benign and malignant breast nodules with a diameter ≤ 1.0 cm [J]. Journal of International Oncology, 2023, 50(9): 520-526.
[14]	Shandong Medical Association Multidisciplinary Joint Committee on Lung Cancer. Shandong Provincial Medical Association multidisciplinary standardized diagnosis and treatment guidelines for esophageal carcinoma （2023 Edition） [J]. Journal of International Oncology, 2023, 50(7): 385-397.
[15]	Ju Yifan, Xu Chenyang, Lei Dapeng. Research progress of pathomics in head and neck neoplasms [J]. Journal of International Oncology, 2023, 50(5): 294-298.